Business Wire

Arm Technology Powers the World’s Fastest Supercomputer

22.6.2020 19:00:00 EEST | Business Wire | Press release

Share

Today at the International Supercomputing Conference (ISC) it was announced that the Fugaku supercomputer, a system jointly developed by RIKEN and Fujitsu Limited, and based on Arm® technology, was awarded the number one spot of the TOP500 list. Having been crowned the world’s most efficient supercomputer on the Green500 list in November 2019, Fugaku was today also given top honors on the HPCG list, a ranking of benchmarks across real-world applications, and the HPL-AI, which rates performance on tasks used in artificial intelligence applications.

“We are incredibly proud to see an Arm-based supercomputer of this scale come to life and thank RIKEN and Fujitsu for their commitment and collaboration,” said Rene Haas, president, IP Group, Arm. “Powering the world’s fastest supercomputer is a milestone our entire ecosystem should be celebrating as this is a significant proof point of the innovation and momentum behind Arm platforms making meaningful impact across the infrastructure and into HPC.”

This achievement represents for the industry a significant evolution in the needs of the modern infrastructure. Compute efficiency is more important than ever, developers are demanding more efficiency and flexibility, and the cloud is driving massive change across the ecosystem. Arm has answered the challenge with its Neoverse™ roadmap and portfolio which aims to deliver the performance, efficiency, and scalability required to enable the next generation of HPC deployments. Arm has also made significant investments across the HPC software ecosystem, enabling seamless migration across instruction sets, cross-platform development, profiling, and debug. Most recently, the company added additional porting capabilities to Arm Compiler for Linux and Arm Allinea Studio to help accelerate applications on current and future Arm CPUs, as more projects of this scale will be based on Arm because of its openness, efficiency, and software ecosystem maturity.

Today’s announcement signals the direction that industry is headed, and through this collaborative effort, a shared purpose of enabling greater choice and flexibility to multiple segments of the infrastructure market has emerged.

The Fugaku supercomputer, which is located at the RIKEN Center for Computational Science, is the flagship system designed to support a number of applications that will address both social and scientific issues as Japan works to achieve “Society 5.0”. Fugaku will accelerate research that spans drug discovery and weather and climate forecasting, to new production processes, and is already being used in the fight against COVID-19 to gain a better understanding of the novel coronavirus.

To learn more about Arm’s journey in HPC, visit the Arm Newsroom.

To read more about the Fugaku supercomputer, read here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristen Ray
armpress@archetype.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release

Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye